Alprazolam Disease area studied Abbreviated title Phase Study ID Registry database Study results Plain language summary Publication (if available) Anxiety A Multicenter, Open-Label, Randomized Crossover Trial to Assess Subject Preference for Alprazolam Orally Disintegrating Tablets Compared to Conventional Alprazolam Tablets in Subjects With Anxiety Phase 3 SP0829 Completed NCT00139854 PDF Mild Asthma A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild Asthma Phase 1 UP0099 Completed NCT04802746 Miller S.D., et al. Neurology 2024; 102(17 Suppl.1), abs P9-1.009 76th Annual Meeting of American Academy of Neurology (AAN), April 13-18, 2024; Denver, USA. Epilepsy A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With Epilepsy Phase 1 UP0100 Completed NCT048573072022-002523-36 LINK Klein P. et al. Neurology 2024; 102(17 Suppl.1), abs P9-1.002 76th Annual Meeting of American Academy of Neurology (AAN), April 13-18, 2024; Denver, USA. Epilepsy A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study Participants Phase 1 UP0104 Completed NCT05626439 PDF Goldwater R., et al. Neurology 2025; 104(7_Supplement_1), P9-9.009 77th Annual Meeting of American Academy of Neurology (AAN), April 05-09, 2025; San Diego, USA
